$7.4 Bil­lion Set­tle­ment With Purdue Pharma in Opi­oid Epidemic

Translate to Spanish or other 102 languages!

exas Attorney General Ken Paxton announced that a bipartisan coalition of states and other parties reached a $7.4 billion settlement in principle with members of the Sackler family and their company Purdue Pharma, Inc. (“Purdue”) for their instrumental role in creating the opioid crisis. Logo Source: Public Domain via Wikimedia Commons. Bad for illustration purposes
exas Attorney General Ken Paxton announced that a bipartisan coalition of states and other parties reached a $7.4 billion settlement in principle with members of the Sackler family and their company Purdue Pharma, Inc. (“Purdue”) for their instrumental role in creating the opioid crisis. Logo Source: Public Domain via Wikimedia Commons. Bad for illustration purposes
- Advertisement -

Texas Attorney General Ken Paxton announced that a bipartisan coalition of states and other parties reached a $7.4 billion settlement in principle with members of the Sackler family and their company Purdue Pharma, Inc. (“Purdue”) for their instrumental role in creating the opioid crisis. 

Purdue, under the Sacklers’ leadership, invented, manufactured, and aggressively marketed opioid products for decades, fueling waves of addiction and overdose deaths across the country. The settlement ends the Sacklers’ control of Purdue and their ability to sell opioids in the United States. Further, it will deliver funding directly to communities across the country over the next 15 years to support opioid addiction treatment, prevention, and recovery programs. The $7.4 billion settlement in principle, the nation’s largest settlement to date with individuals responsible for contributing to the opioid crisis, comes after the United States Supreme Court overturned a prior multistate settlement with the Sacklers and Purdue in June 2024.

“For years, I have aggressively worked to hold Purdue Pharma and other corporations accountable for their roles in creating and exacerbating the deadly opioid crisis that harmed so many Americans,” said Attorney General Paxton. “While nothing can restore the damage done, this settlement will provide Texans valuable resources to help prevent more opioid abuse. It was an honor to help lead these negotiations and I will never stop ensuring that justice is secured for those affected.” 

- Advertisement -

Attorney General Paxton has been a national leader in holding companies accountable for their roles in the opioid crisis, securing over $3 billion in settlements with Johnson & JohnsonWalmartWalgreensCVS, and other companies. 

Joining Attorney General Paxton in securing the settlement in principle are the attorneys general of California, Colorado, Connecticut, Delaware, Florida, Illinois, Massachusetts, New York, Oregon, Pennsylvania, Tennessee, Vermont, Virginia, and West Virginia.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Annual ‘Chalk the Walk’ Event Inspires Connection

Approximately 2.2 million Americans attempted suicide in 2024, according to the American Foundation for Suicide Prevention, while nearly 50,000 lives were lost to suicide. 

DHR Health’s Free Seminar on Breakthrough Treatment for Stroke Survivors, Sept. 19th

DHR Health’s Neuroscience Institute will host a free seminar for stroke survivors who want improved hand and arm movement as many stroke survivors experience impaired mobility and loss of function in the arm which can significantly affect their ability to   perform everyday activities.

STHS Heart’s Intensive Cardiac Rehab Program Earns AACVPR Recertification

Each year, more than 800,000 people in the United States experience a heart attack, according to the American Heart Association, and approximately one in four of those events are repeat occurrence

Newly Discovered Genetic Eye Disease Triggers Night Blindness and Tunnel Vision

Scientists identified a new vision condition linked to a gene already connected to a different vision-loss disease. While the previously identified disease causes loss of central vision, the new condition affects peripheral and night vision.
- Advertisement -